眼部移植物抗宿主病的研究进展

doi:DOI:10.3760/cma.j.issn.1674-845X.2016.05.015

Abstract
Figure/Table
References (27)
Related Citation (1)

Download: PDF (5225 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract

Hematopoietic stem cell transplantation (SCT) is a reliable treatment for malignant hematological diseases. After receiving an allogeneic SCT, graft-versus-host disease is a major cause of death and disability. Depending on the time of its origin and clinical manifestations, GVHD can be divided into acute and chronic types. Acute GVHD is defined as a syndrome involving the skin, gastrointestinal tract, and liver. Chronic GVHD is defined as a syndrome and involves organs that typically include the skin, mouth, liver, gastrointestinal tract, lungs, and eyes. After receiving allogenic hematopoietic stem cell transplants, about 40%-60% of the patients will suffer from acute or chronic graft-versus-host disease, a disease that can lead to several serious ocular diseases and greatly affects the quality of life of patients. However, guidelines for treatment have not been issued so far. This paper provides an overview of the latest research progress on ocular HVGD and emphasizes the urgency for its prevention.

Key words： Graft vs host disease Ocular graft vs host disease Hematopoietic stem cell transplantation

Received: 18 November 2015

Corresponding Authors: Zhu Dan, Emali: zhudan1968@163.com

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Zheng Yanfei
	Zhu Dan

Cite this article:

Zheng Yanfei,Zhu Dan. Current research on ocular graft-versus-host disease [J]. Chinese Journal of Optometry Ophthalmology and Visual science, 2016, 18(5): 314-320.

URL:

https://www.cjoovs.com/EN/DOI:10.3760/cma.j.issn.1674-845X.2016.05.015 OR https://www.cjoovs.com/EN/Y2016/V18/I5/314

[1]	Sun YC, Chai X, Inamoto Y, et al. Impact of ocular chronic graft-versus-host disease on quality of life[J]. Biol Blood Marrow Transplant,2015,21(9):1687-1691. DOI:10.1016/j.bbmt.2015.05.020.
[2]	Vigorito AC, Campregher PV, Storer BE, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD[J]. Blood,2009,114(3):702-708. DOI:10.1182/blood-2009-03-208983.2009.03.020.
[3]	李喜梅,朱恒,周凡,等. 慢性移植物抗宿主病的发病机制及其相关问题最新研究进展[J]. 中国实验血液学杂志,2014,22(2):549-554. DOI:10.7534/j.issn.1009-2137.2014.02.053.
[4]	Lee SJ, Flowers ME. Recognizing and managing chronic graft-versus-host disease[J]. Hematology Am Soc Hematol Educ Program,2008,134-141. DOI:10.1182/asheducation-2008.1.134.
[5]	Couriel DR. Ancillary and supportive care in chronic graft-versus-host disease[J]. Best Pract Res Clin Haematol,2008,21(2):291-307. DOI:10.1016/j.beha.2008.02.014.
[6]	Filipovich AH. Diagnosis and manifestations of chronic graft-versus-host disease[J]. Best Pract Res Clin Haematol,2008,21(2):251-257. DOI:10.1016/j.beha.2008.02.008.
[7]	Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy[J]. Nat Rev Immunol,2012,12(6):443-458. DOI:10.1038/nri3212.
[8]	Arora M, Cutler CS, Jagasia MH, et al. Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation[J]. Biol Blood Marrow Transplant,2016,22(3):449-455. DOI:10.1016/j.bbmt.2015.10.018.
[9]	Holler E. Risk assessment in haematopoietic stem cell transplantation: GVHD prevention and treatment[J]. Best Pract Res Clin Haematol,2007,20(2):281-294. DOI:10.1016/j.beha.2006. 10.001.
[10]	Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, et al. The role of B cells in the pathogenesis of graft-versus-host disease[J]. Blood,2009,114(24):4919-4927. DOI:10.1182/blood-2008-10-161638.
[11]	Olivieri A, Locatelli F, Zecca M, et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features[J]. Blood, 2009,114(3):709-718. DOI:10.1182/blood-2009-02-204156.
[12]	Rossi P, Delcampe A, Gueudry J, et al. Gas-permeable scleral lens for management of severe keratoconjunctivitis sicca secondary tochronic graft-versus-host disease[J]. J Fr Ophtalmol,2015,38(9):793-799. DOI:10.1016/j.jfo.2015.04.012.
[13]	Tabbara KF, Al-Ghamdi A, Al-Mohareb F, et al. Ocular findings after allogeneic hematopoietic stem cell transplantation[J]. Ophthalmology,2009,116(9):1624-1629. DOI:10.1016/j.ophtha.2009. 04.054.
[14]	Westekemper H, Meller S, Citak S, et al. Differential chemokine expression in chronic GVHD of the conjunctiva[J]. Bone Marrow Transplant,2010,45(8):1340-1346. DOI:10.1038/bmt.2009.346.
[15]	Beres AJ, Drobyski WR. The role of regulatory T cells in the biology of graft versus host disease[J]. Front Immunol,2013,4:163. DOI:10.3389/fimmu.2013.00163.
[16]	Flynn R, Du J, Veenstra RG, et al. Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans[J]. Blood,2014,123(25):3988-3998. DOI: 10.1182/blood-2014-03-562231.
[17]	Ogawa Y, Yamazaki K, Kuwana M, et al. A significant role of stromal fibroblasts in rapidly progressive dry eye in patients with chronic GVHD[J]. Invest Ophthalmol Vis Sci,2001,42(1):111-119.
[18]	Rojas B, Cuhna R, Zafirakis P, et al. Cell populations and adhesion molecules expression in conjunctiva before and after bone marrow transplantation[J]. Exp Eye Res,2005,81(3):313-325. DOI:10.1016/j.exer.2005.02.004.
[19]	Eisenberg RA, Via CS. T cells, murine chronic graft-versus-host disease and autoimmunity[J]. J Autoimmun,2012,39(3):240-247. DOI:10.1016/j.jaut.2012.05.017.
[20]	Couriel DR. Ancillary and supportive care in chronic graft-versus-host disease[J]. Best Pract Res Clin Haematol,2008,21(2):291-307. DOI:10.1016/j.beha.2008.02.014.
[21]	Wang Y, Ogawa Y, Dogru M, et al. Baseline profiles of ocular surface and tear dynamics after allogeneic hematopoietic stem cell transplantation in patients with or without chronic GVHD-related dry eye[J]. Bone Marrow Transplant,2010,45(6):1077-1083. DOI:10.1038/bmt.2009.312.
[22]	Wolff D, Gerbitz A, Ayuk F, et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD[J]. Biol Blood Marrow Transplant,2010,16(12):1611-1628. DOI:10.1016/j.bbmt.2010.06.015.
[23]	Blecha C, Wolff D, Holler B, et al. Verification of the new grading scale for ocular chronic graft-versus-host disease developed by the German-Austrian-Swiss consensus conference on chronic GVHD[J]. Ann Hematol,2016,95(3):493-499. DOI:10.1007/s00277-015-2575-9.
[24]	Dietrich-Ntoukas T, Cursiefen C, Westekemper H, et al. Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss consensus conference on clinical practice in chronic GVHD[J]. Cornea,2012,31(3):299-310. DOI: 10.1097/ICO.0b013e318226bf97.
[25]	Wolff D, Schleuning M, von Harsdorf S, et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease[J]. Biol Blood Marrow Transplant,2011,17(1):1-17. DOI:10.1016/j.bbmt.2010.05.011.
[26]	Haase D, Starke M, Puan KJ, et al. Immune modulation of inflammatory conditions: regulatory T cells for treatment of GVHD[J]. Immunol Res,2012,53(1-3):200-212. DOI:10.1007/s12026-012-8267-9.
[27]	Colonna L, Florek M, Leveson-Gower DB, et al. IL-17 gene ablation does not impact Treg-mediated suppression of graft-versus-host disease after bone marrow transplantation[J]. Biol Blood Marrow Transplant,2013,19(11):1557-1565. DOI:10.1016/j.bbmt.2013.07.024.